Abstract
In any given year, 2.5 percent of the population experiences treatment resistant depression (TRD). TRD is estimated to cost 60-100 billion per year to treat in the US. Electroconvulsive therapy (ECT) is effective for TRD with remission rates ranging from 50 to 75 percent. However, ECT use in TRD is limited to fewer than 1 percent of patients due to fear, stigma and memory side effects. Repetitive transcranial magnetic stimulation (rTMS) and magnetic seizure therapy (MST) offer a viable alternative to ECT with treatment results suggesting significant mood improvement in TRD. These treatments are also associated with significant rates of remission of suicidal ideation (SI). In this presentation, rTMS and MST will be discussed in detail. Novel rTMS and MST treatment approaches will also be discussed
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
